Compare Salesforce Inc (CRM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Novartis AG — how do they compare? Salesforce Inc trades at $228.83 (market cap $187.48B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Novartis AG for 82 Days on average.
| CRM | NVS | |
|---|---|---|
Market Cap | $187.48B | $268.57B |
Volume | 6,155,822 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $266.23 | $168.62 |
52-Week Low | $150.12 | $121.80 |
Typical Hold Time | 89 Days | 82 Days |
Enterprise Value | $217.82B | $309.89B |
Dividend Yield | 0.77% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected), robust profitability (77.28% gross margin, 21.99% net margin), and healthy cash flow generation ($13.09B operating cash flow in 2025). Technical indicators remain bearish with current price near pivot point support at $224.
Outlook remains positive long-term given Salesforce's dominant market position, AI monetization growth (Agentforce ARR up 107% quarterly), and analyst consensus target of $271.91 (21% upside). Near-term risks include software sector volatility and competitive AI threats, but strong fundamentals support recovery potential from current discounted valuation levels.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
